The US Peace Corps said it was withdrawing 340 volunteers from Liberia, Sierra Leone and Guinea due to the spreading Ebola virus across West Africa.» Read More
Pfizer has renewed its interest in a takeover of UK rival AstraZeneca, in what would be one of the global drugs industry’s largest ever deals.
Oregon's deeply troubled state-run Obamacare exchange votes to have the federal exchange HealthCare.gov take over enrollment for residents.
The electronic cigarette industry reacted positively to proposed FDA regulations which could bring further legitimacy to the nicotine vapor devices.
The federal patient privacy watchdog obtained a $1.7 million settlement for lax data security practices from a leading health treatment provider. This may only be a taste of things to come.
It's "too early to tell" if President Barack Obama's signature health care law is successful, Aetna CEO Mark Bertolini told CNBC.
Allergan may be more effective in its defense against a hostile takeover bid by Valeant Pharmaceuticals if it makes a purchase of its own, an analyst says.
The chief executive of AstraZeneca, at the center of speculation of a $101 billion takeover, has said such large-scale deals are "often disruptive."
Novartis posted first-quarter profit that beat expectations, boosted by an exceptional gain from the sale of its blood transfusion test unit.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
Gilead's net profit nearly tripled and revenue was more than $1 billion ahead of estimates, thanks to sales of a key Hepatitis C drug.
More than half the revenue from Botox comes from therapeutic, not cosmetic, use. And its potential is helping to make Allergan an attractive target.
Male doctors on average make 88 percent more in Medicare reimbursements than female physicians, according to an analysis of government data.
The megabillion-dollar deals with Novartis also allow GlaxoSmithKline to "significantly expand" its world-leading vaccine business, GSK's CEO tells CNBC.
Pharmaceutical industry observers have been waiting for a rush of deals for months - and they might have finally arrived.
JPMorgan Chase's Mike Weinstein gives his top health care picks to buy right now, in light of recent weakness in the sector.
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
Activist investor William Ackman of Pershing Square Capital and Valeant Pharmaceuticals International are said to be pursuing a takeover of Allergan.
Biotech earnings kick off Tuesday after the bell as Gilead and Amgen report. Here's what to watch for.
Sarepta Therapeutics got the go-ahead to file for approval of its experimental drug for Duchenne muscular dystrophy.
HealthCare.gov warned enrollees that their passwords had been reset to guard against the "Heartbleed" bug.
Get the best of CNBC in your inbox